ZARS, Inc. is a specialty pharmaceutical company focused on the development and commercialization of topically applied drugs using its proprietary drug delivery technologies, primarily in the area of pain management. ZARS has developed a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery (CHADD) and its phase-changing cream (Peel and DuraPeel) technologies. The Companys products and product candidates include two products that have been approved for marketing (Pliaglis and Synera), one product candidate for which it has initiated the first of two Phase 3 clinical trials (ThermoProfen) and two product candidates which are in Phase 1 clinical trials.